Molecular Partners AG
MOLN
Clasificación en acciones
#19468
Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to... Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and bringing to market novel therapeutic proteins. Leveraging its proprietary DARPin® platform, the company is advancing a diverse pipeline of product candidates. Key among these is Abicipar, a DARPin-based treatment currently in Phase III clinical development for significant ophthalmic conditions like neovascular wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Additionally, their portfolio features multi-specific DARPin candidates targeting infectious diseases, such as MP0420 and MP0423, both designed to combat the SARS-CoV-2 virus (COVID-19). In the oncology space, Molecular Partners is advancing several programs: MP0310, in Phase Ia for immuno-oncology; MP0317, a Phase I tumor-localized immune agonist engineered to activate immune cells within tumors; and MP0274, also in Phase I, aimed at HER2-positive cancers. Further early-stage assets include MP0533, a CD3 T cell candidate for acute myeloid leukemia, and MP0250, which targets vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and human serum albumin (HSA) to enhance therapeutic half-life. The company actively collaborates with leading pharmaceutical companies. Notable alliances include a partnership with Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; agreements with Amgen SA and Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc. They also maintain relationships with various other third-party collaborators. Established in 2004, Molecular Partners AG is headquartered in Schlieren, Switzerland.
Precio por acción
$3.99
Última sincronización: 2026-10-20
Capitalización bursátil
$152.94M
Cambio (1 día)
0.33%
Cambio (1 año)
11.60%
País
CH
Comercio Molecular Partners AG (MOLN)
Categoría
Healthcare
Historial de dividendos de Molecular Partners AG (MOLN)
Molecular Partners AG (símbolo bursátil: MOLN) realizó un total de 0 pagos de dividendos.
La suma de todos los dividendos (ajustados por splits de acciones) es: 0.00
Rentabilidad por dividendo (TTM): 0
La suma de todos los dividendos (ajustados por splits de acciones) es: 0.00
Rentabilidad por dividendo (TTM): 0
Pagos de dividendos de Molecular Partners AG (MOLN) desde 2026 hasta 2026
Pagos anuales de dividendos
| Año | Dividendo (ajustado por splits de acciones) | Cambiar |
|---|---|---|
| Not enough data for the provided dates. | ||
Lista de todos los pagos de dividendos
| Año | Dividendo | Cambiar |
|---|---|---|
| Not enough data for the provided dates. | ||
Pagos de dividendos de empresas similares o competidoras
| Empresa | Número de pagos de dividendos | País |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 64.00% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
